title: Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.
abstract: We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N',N"-triethylenethiophosphoramide (thiotepa). The cell lines studied included HuTu-80 (duodenum), HT-29 (colon), ME-180 (cervix), and A-427 (lung). A 48- to 72-h pretreatment with DFMO reduced intracellular putrescine and spermidine contents to less than 10% and less than 1% of control levels. This treatment also caused a 30%-70% decline in spermine content. Survival of control and DFMO-pretreated cells after treatment with chlorambucil or thiotepa was measured by a plating efficiency assay. For three of the four lines studied, the DFMO-induced partial polyamine depletion significantly protected cells from the lethal effects of chlorambucil. In ME-180 cultures alone, DFMO pretreatment did not alter the cytocidal efficacy of chlorambucil. Addition of exogenous putrescine to cultures of HuTu-80, HT-29, or A-427 24 h after DFMO addition but 24 h before treatment with chlorambucil reversed the polyamine depletion and its protective effects on chlorambucil-induced cell kill. In contrast to the above observations, DFMO and partial polyamine depletion had no effect on cell survival after thiotepa treatment for any of the cell lines investigated.
authors.forename: J
authors.initials: J
authors.lastname: Seidenfeld
authors.forename: K A
authors.initials: KA
authors.lastname: Komar
authors.forename: M F
authors.initials: MF
authors.lastname: Naujokas
authors.forename: A L
authors.initials: AL
authors.lastname: Block
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism; D000477:Alkylating Agents / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002699:Chlorambucil / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000378:metabolism; D000518:Eflornithine; D006801:Humans; D009952:Ornithine / Q000031:analogs & derivatives* / Q000494:pharmacology; D065108:Ornithine Decarboxylase Inhibitors; D011073:Polyamines / Q000502:physiology*; D013852:Thiotepa / Q000494:pharmacology
chemical_list: D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D065108:Ornithine Decarboxylase Inhibitors; D011073:Polyamines; D002699:Chlorambucil; D013852:Thiotepa; D009952:Ornithine; D000518:Eflornithine